Cord blood is the blood left over in the umbilical cord and placenta after a baby is born.
Umbilical Cord Blood (UCB), once regarded as biological waste, has become an accepted source of hematopoietic stem cells/hematopoietic progenitor cells (HSCs/HPCs). Umbilical cord blood stem cells are not embryonic, they are more pristine than the stem cells in adults, because they are younger and they have less exposure to illness or environmental factors.
The major sources of stem cells in the human body are umbilical cord blood, bone marrow and peripheral blood progenitor cells.
Cord blood banking refers to the whole process of collecting and preserving the stem cells that remain in the blood of the umbilical cord and the placenta after the birth of a baby.
Cord Blood Stem Cells are very pristine and naïve cells which has unique properties such as self-renewal and differentiation. Since the first cord blood transplant in 1988, cord blood stem cells have shown promising outcomes treating in many conditions. Currently 80+ conditions are approved for treatment with Cord Blood Stem Cells and more than 100 clinical trails are performed across the globe to find out the hidden potential of these magical cells.
Cord blood stem cells offer many advantages over other sources of stem cells, including
- Cord blood is easy to collect.
- The collection procedure is quick and very safe and poses no risk or discomfort to the mother or baby.
- Less time is needed for processing (more quickly available for use).
- Less costly than other sources.
- Cord blood stem cells can be successfully used even when there is no exact match between donor and recipient whilst by another source of transplant one requires a perfect match and finding a donor is also difficult and time-consuming.
- Cord blood stem cells have a great capacity to proliferate.
Umbilical cord blood stem cell banking is a means to safeguard and invest in your baby and family’s future health. Cord Blood cells are genetically unique and are a 100% match for the same child. The probability of a match is higher for siblings and may be a good match for other family members too.
We encourage expectant mothers to register for cord blood banking in between the 12th-34th week of pregnancy. For the collection procedure to take place in a smooth way we request you to register as early as possible to avoid any last-time rush.
In the event that you decide to avail of our services just a few days prior to the birth of your baby, you have to notify and register with us at least 48 hours before delivery for avoiding last minute rush. We shall try our best to collect the cord blood so that you do not miss this opportunity.
Contact us on our Toll-Free number 1800 120 0086 or you can visit our website www.stemcyteindia.com to book an appointment with our expert.
Immediately after the delivery of the baby, the umbilical cord is clamped and the cord blood is collected once the baby is separated from cord and mother.
Cord blood is collected by obstetrician–gynecologist (ob-gyn) or the trained staff at the hospital at the time of child’s birth.
The umbilical cord blood is collected via sterile technique. Once the baby is delivered, the umbilical cord is clamped and cut. Blood is drawn from the cord with a needle that has a bag attached. The process takes about 10 minutes.
Not at all. The collection procedure is painless and poses no risk to the mother or baby.
No. StemCyte India will provide you a cord blood collection kit at time of registration which has all necessary material for collection.
Once the collection kit is handed over to you, follow the instruction written on the collection kit box. Take the collection kit box along to the hospital at the time of delivery.
Firstly, try and obtain the kit from your home or from the location it is kept along with that intimate immediately regarding the situation to StemCyte India. We will try our level best to arrange a spare kit box from hospital or through our representative.
StemCyte India executive / collection nurse will do the necessary formalities for shipping. We are associated with leading logistics company for arranging safe, smooth and X-ray free shipping to our processing laboratory.
Once the cord blood is collected after the child’s birth, it reaches to our laboratory within the stipulated timeline. After performing required tests and validation, cord blood is preserved with utmost safety and security by following stringent national and international guidelines and procedures. Finally, the cord blood unit is preserved in liquid nitrogen (-196° C) tanks.
StemCyte India customer care team will intimate you once the cord blood unit reaches our laboratory. Also, you will receive confirmation form our customer care team once the unit is successfully preserved in our laboratory.
StemCyte is a global cord blood bank and pioneer in regenerative therapeutics that operates internationally in USA (1997), Taiwan (2000), and India (2010). StemCyte India is a joint venture between StemCyte USA, Apollo Hospitals and Cadila Pharmaceuticals and was established in 2010.
StemCyte India Therapeutics Pvt. Ltd. is located at the Apollo Hospital campus Gandhinagar, Gujarat.
StemCyte India offers a very unique cord blood banking model, the Hybrid banking model.
- Private Banking: UCB is collected, processed, and stored solely for the future medical needs of the child or family.
- Public Banking: the UCB is donated to StemCyte for processing & storage, for therapeutic use by unrelated patients.
StemCyte India has all accreditations and certifications, which are internationally recognized and accepted to ensure that the company has been assessed by independent peer experts for having the competence, reliability, operational performance, and quality management of the processing and cryopreservation protocols to ensure patient safety at the time of transplant.
StemCyte India is accredited with FACT, AABB, DCGI, NABL, ISO-9001, FDA, and ISBT 128, and member of CBA.
StemCyte uses proprietary Plasma Depletion (PD) technology for processing and preservation of cord blood. PD Technology ensures higher recovery of TNC and CD34+ count, Better Engraftment rates and Highest Preserved Volume.
Globally, StemCyte has provided 2200+ Cord Blood Units in 350+ transplant centers including 48 units in India.